Neuron23

Precision medicine for Parkinson’s, powered by data, genetics, and innovative trials.

[Neuron23 @official_N23]

The NEULARK trial (NCT06680830) doesn’t run itself. Meet our 4 MSLs driving scientific engagement on the ground. They’re the link between our science and the investigators advancing it in the clinic.

[Neuron23 @official_N23]

We're grateful for the support of the @MichaelJFoxOrg. As we open new study sites, we're able to connect with more individuals with #Parkinsons disease and advance research focused on targeting LRRK2 overactivity to potentially slow disease progression.

[Parkinson's News Today @parkinsonstory]

Neuron23 will use an MJFF grant to expand a Phase 2 clinical study testing NEU-411 in people with early Parkinson’s disease

#parkinsons #parkinsonsdisease #parkinsonsresearch #parkinsonstreatment https://t.co/3Rh5XoWXSF

[Neuron23 @official_N23]

Honored to receive a $2.5M grant from @MichaelJFoxOrg to expand our NEULARK Phase 2 trial of NEU-411 into Israel, bringing precision medicine closer to people with LRRK2-driven #Parkinsons.

Read more: https://t.co/oPaMfjn2We

[Neuron23 @official_N23]

Several Neuron23 team members attended #WPC2026 in Phoenix last week. Because we focus on LRRK2-targeted therapy, being in the room with the global Parkinson's research community is exactly where we need to be.

[Neuron23 @official_N23]

We’re pleased to collaborate with the @ParkinsonDotOrg's on the PD Trial Navigator pilot program, designed to identify individuals whose Parkinson’s is LRRK2-driven in order to potentially match them to clinical programs such as our NEULARK trial.
https://t.co/AmbsXTAHrs

[Neuron23 @official_N23]

A clinical trial isn't something done to patients. It's something built with them.

This #ClinicalTrialsDay, thank you to the global #ParkinsonsDisease community shaping the future of precision medicine alongside us.

[Neuron23 @official_N23]

Our 4th year at the annual #MovingDayWalk in San Jose! At Neuron23, our work begins & ends with patients, so we’re grateful for @ParkinsonDotOrg, and everyone committed to driving real impact for people living with Parkinson’s disease.

[Neuron23 @official_N23]

Parkinson’s awareness doesn’t end in April. Millions continue navigating a disease still too often treated as one-size-fits-all. At Neuron23, we’re advancing research, including ongoing clinical studies, to better understand its biology and move toward more precise approaches.

[Neuron23 @official_N23]

This weekend, CEO Nancy Stagliano & Madeline Boyer joined the 2026 Parkinson’s Unity Walk with the Michael J. Fox Foundation.

A reminder that progress in Parkinson’s is driven by a connected community. Proud to move alongside it toward more targeted, effective treatment options.

[Neuron23 @official_N23]

This April, we recognize #ParkinsonsAwarenessMonth as a time to raise awareness of a disease affecting 10M+ people worldwide. At Neuron23, we’re advancing precision medicine to better understand PD and develop more targeted therapies that address underlying causes of the disease.

[Neuron23 @official_N23]

Check your eligibility: https://t.co/u7MxUZiHEm

[Neuron23 @official_N23]

#ParkinsonsDisease (PD) is biologically complex, and not all forms of PD are the same.

Our study involves an investigational next-generation sequencing diagnostic tool developed in collaboration with QIAGEN to help identify people with LRRK2-driven PD.

[Neuron23 @official_N23]

Members of our leadership team attended #ADPD2026, where the global Parkinson’s research community gathers to share advances and strengthen collaboration. At Neuron23, we’re advancing precision medicine to develop therapies for #ParkinsonsDisease.

[Neuron23 @official_N23]

We're identifying genetic signatures that are correlated with increased activity in LRRK2, which is implicated in PD. Learn more about our science here: https://t.co/PXI6ptJmFo

[Neuron23 @official_N23]

#ParkinsonsDisease is the 2nd most common neurodegenerative disease.

Today, there are no therapies available that slow the underlying progression.

Current treatment options are only used to manage symptoms.

At Neuron23, our precision approach aims to change the paradigm.

[Neuron23 @official_N23]

Parkinson’s disease is progressive, & over time, symptoms worsen.

The NEULARK study is evaluating whether NEU-411, an investigational oral therapy, may help slow the progression of PD.

Learn more about our global NEULARK study here: https://t.co/jX5cg0mtfV

[Neuron23 @official_N23]

Our intention is simple, but our work is not.

Follow along, and learn more about our approach to treating people living with LRRK2- driven Parkinson’s disease at https://t.co/hWJAg1Ybhd

[Neuron23 @official_N23]

Today on World Movement Disorders Day, we recognize the impact of #Parkinsons & this year’s theme: “What Moves You?” Nearly 90,000 are diagnosed each year in the U.S., with <9M affected worldwide. We stand with patients, caregivers, & the community driving progress. #MoveDisorder

[Neuron23 @official_N23]

That’s a wrap on #MDSCongress 2025! Grateful for the chance to share additional Phase 1 results of our LRRK2 inhibitor NEU-411 and connect with so many working to advance care for people living with #Parkinsons.

[Neuron23 @official_N23]

We’re looking forward to the 2025 #MDSCongress, where we’ll share Phase 1 results of NEU-411 in healthy participants and showcase our NEULARK trial at our booth.

Visit us to learn more about our work and the future of precision medicine in #Parkinsons.